(5)
|
This on-demand course has been approved by the Wisconsin Medical Examining Board as meeting the requirements for continuing education on responsible opioid prescribing per Med 13.03(3) of the Wisconsin Administrative Code. This course will need to be combined with additional education to meet the two-hour requirement.
Please note, updated disclosures: None of the faculty or planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
This activity has been pre-approved for ABIM, ABA, ABP, ABOHNS, ABS, and ABPath MOC Part II credit. Approval for MOC Part II credit by other ABMS Boards may be found here. Participants who complete the activity by Dec. 1, 2024, will have their MOC credit submitted for 2024; after Dec. 1, 2024, MOC credits will be submitted for 2025.
Speaker: David Galbis-Reig, MD, DFASAM, Medical Director of Addiction Services at Wheaton Franciscan Healthcare – All Saints, Racine, WI
Management of chronic pain with opioid analgesics is associated with certain morbidity and mortality risks. Physicians can minimize risk to patients by use of ongoing drug monitoring technologies. This webinar will introduce prescribers to the art and science of drug testing including the use of different drug testing matrices and an explanation regarding the differences between screening immunoassay technology and confirmatory GC-MS or LC-MS testing. Through this webinar, participants will learn how to use currently available urine drug screening technology in everyday clinical practice settings including appropriate use of confirmatory tests to maximize accuracy for clinical interpretation. The appropriate incorporation of drug testing into a variety of clinical practice settings will also be discussed.
Objectives
1. Review the history of drug testing and its introduction into clinical practice.
2. Describe the different drug testing matrices and the potential advantages and disadvantages of each in clinical practice.
3. Identify the basics of drug testing: what to test, how to test, and in what situations to perform a urine drug screen.
4. List the limitations of urine drug testing.
5. Interpret a positive urine immunoassay and identify when to obtain confirmatory tests.
Release Date (enduring material): August 1, 2023
Review Date: July 2023
Expiration Date: August 1, 2026
Method of Participation
Prior to viewing the presentation, participants must complete a brief pre-test. Participants view the presentation and listen to the synchronized audio of the recorded lecture. After viewing the presentation, participants must complete an evaluation and a post-test in which they must answer at least 75% of the answers correctly in order to receive AMA PRA Category 1 Credit™. The participant cannot proceed to request credit until this score is achieved.
Contact Information
E-mail education@wismed.org for questions related to the educational content.
Target Audience
This activity is designed for Primary Care Physicians, Specialty Physicians, Allied Health Professionals, Nurses, Social Workers, and Professional Staff.
Commercial Support:
No commercial support was used in creating this educational activity.
ADA Compliance Statement:
In accordance with the Americans with Disabilities Act, the Wisconsin Medical Society seeks to make this activity accessible to all. If you have a disability, which might require special accommodations, please call 608.442.3800.
Refund policy:
Registration is not refundable. If you are unable to participate in an activity for which you are registered, you may have a substitute participate in your place.
Adding Registration, Please wait...
